In Alzheimer’s Disease, 6-Month Treatment with GLP-1 Analog Prevents Decline of Brain Glucose Metabolism: Randomized, Placebo-Controlled, Double-Blind Clinical Trial

In animal models, the incretin hormone GLP-1 affects Alzheimer’s disease (AD). We hypothesized that treatment with GLP-1 or an analog of GLP-1 would prevent accumulation of Aβ and raise, or prevent decline of, glucose metabolism (CMR(glc)) in AD. In this 26-week trial, we randomized 38 patients with...

Descripción completa

Detalles Bibliográficos
Autores principales: Gejl, Michael, Gjedde, Albert, Egefjord, Lærke, Møller, Arne, Hansen, Søren B., Vang, Kim, Rodell, Anders, Brændgaard, Hans, Gottrup, Hanne, Schacht, Anna, Møller, Niels, Brock, Birgitte, Rungby, Jørgen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2016
Materias:
Neuroscience
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4877513/
https://www.ncbi.nlm.nih.gov/pubmed/27252647
http://dx.doi.org/10.3389/fnagi.2016.00108

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4877513/
https://www.ncbi.nlm.nih.gov/pubmed/27252647
http://dx.doi.org/10.3389/fnagi.2016.00108

Ejemplares similares